AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec

Novo Nordisk – From market darling to hidden gem?

Novo Nordisk is a heavyweight in the pharmaceutical sector specializing in diabetes and obesity medications. Its best-known product, the weight loss drug Wegovy, has catapulted the Company into the absolute top tier in recent years. Together with its US competitor Eli Lilly, it dominates the market for modern metabolic therapies. The barriers to entry in this field are enormous, characterized by long development times, high regulatory hurdles, and billions in investments in production and distribution. This dominant position caused the Company's valuation to skyrocket, driven by almost unbridled growth expectations.

But the exaggerated expectations collided with reality. The Company was forced to revise its growth forecasts downwards several times. The reasons for this were production bottlenecks that could not meet the strong demand for Wegovy, as well as intensifying competitive pressure. Added to this were regulatory uncertainties, price pressure, and the high costs of urgently needed expansion of production capacity. In this tense situation, management changes and restructuring measures also led to uncertainty.

Even if the exorbitant growth rates of the early days can no longer be achieved, the global market for obesity therapies will continue to grow in the coming years. Novo Nordisk has the potential to benefit from this trend thanks to its deep integration in production and distribution and a robust pipeline. Particularly promising is the development of an oral version of Wegovy, which could significantly expand the pool of potential patients. For investors who are prepared to sit out the current turbulence, the Company could prove to be an interesting entry point into a structurally growing business segment. The share price is currently trading at EUR 50.52.

NetraMark Holdings – When AI makes clinical trials smarter

Clinical trials are the backbone of the pharmaceutical industry, yet their high risk of failure costs billions. This is precisely where NetraMark steps in with an innovative approach. Instead of relying on historical data like many of its competitors, the Company applies its AI platform, NetraAI, directly to data from ongoing or completed studies. A specialized algorithm identifies hidden patterns and divides patients into explainable subgroups. This helps to understand the effectiveness of therapies more precisely and to better predict side effects. For the pharmaceutical industry, this represents an opportunity to design studies in a more targeted manner and reduce costly failures.

Growth is driven by strategic alliances. A global partnership with the contract research organization Worldwide Clinical Trials paves the way to numerous customers in the pharmaceutical industry. Collaboration with Pentara aims to use AI to monitor data integrity in study centers. In addition, partnerships with Asklepion Pharmaceuticals in pediatrics and a leading US research center for aggressive glioblastoma provide concrete use cases. These projects demonstrate the broad applicability of the technology across different therapeutic areas and study phases.

The combination of technological strength and a growing partner network optimally positions NetraMark in a growing billion-dollar market. The pharmaceutical industry has an enormous need to make its studies more efficient and meaningful, a demand that AI is increasingly able to address. NetraMark's stated goal is to use its AI to address this very issue and fundamentally improve the development process for new drugs. The partnerships already established with well-known players are a strong indication that the industry has recognized the solution. Analysts at Zacks Small-Cap Research see a price target of CAD 2.25. The stock is currently trading at CAD 1.37.

Evotec – Where does the drug developer really stand?

The latest figures from Hamburg-based life sciences company Evotec paint a picture of contrasts. In the first half of the year, the Company suffered a decline in revenue of around 5% to EUR 371 million. This weakness was driven by its core business of drug discovery (D&PD), where revenues slumped by 11%. However, there is a clear ray of hope. The Just – Evotec Biologics (JEB) division grew strongly by 16%. This contrasting development underscores the strategic change that has been initiated. Evotec is deliberately transforming itself from a capital-intensive service provider to a scalable technology provider that relies on proprietary platforms.

This realignment is being driven by groundbreaking partnerships. The collaboration with Bristol Myers Squibb in the areas of neurodegeneration and targeted protein degradation not only generates significant milestone payments but also anchors Evotec deeply in innovative fields of research. At the same time, the alliance with Sandoz is being realigned. The planned sale of the biologics production site in Toulouse is intended to free up capital and further advance the asset-light model. The focus is thus shifting definitively from in-house production to licensing the promising perfusion-based manufacturing technology.

For investors, the situation represents a trade-off between short-term weakness and long-term potential. While performance is dampened by the downturn in the D&PD business, strict cost discipline limited the EBITDA loss to EUR 1.9 million. Despite these operational challenges, analysts see significant upside potential, supported by the more profitable JEB division and the expected market recovery in the active ingredient market. Investors confident in the Company's technology transformation and platform strength may view the current consolidation as a buying opportunity. In August and September, two of the Company's executive bodies purchased shares totaling around EUR 370,000 at approximately EUR 5.92. The share is currently trading at EUR 6.83.

The AI-driven race for the next blockbuster drugs is in full swing, but the paths taken by the companies could not be more different. Following its growth dip, Novo Nordisk must now deliver and overcome production bottlenecks in order to realize its enormous sales potential. NetraMark Holdings scores as an AI specialist with clever solutions to make clinical trials more efficient and meaningful. Meanwhile, Evotec is in the midst of a painful but necessary strategic shift from service provider to scalable technology provider. Those who master AI today will write billion-dollar success stories tomorrow.